239 related articles for article (PubMed ID: 34950677)
1. Cefiderocol: An Overview of Its
Yao J; Wang J; Chen M; Cai Y
Front Med (Lausanne); 2021; 8():741940. PubMed ID: 34950677
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
3. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
Karakonstantis S; Rousaki M; Vassilopoulou L; Kritsotakis EI
Clin Microbiol Infect; 2024 Feb; 30(2):178-188. PubMed ID: 37666449
[TBL] [Abstract][Full Text] [Related]
4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
6. High efficacy and enhanced synergistic activity of the novel siderophore-cephalosporin cefiderocol against multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae from inpatients attending a single hospital in the United Arab Emirates.
Daoud L; Al-Marzooq F; Ghazawi A; Anes F; Collyns T
J Infect Public Health; 2023 Dec; 16 Suppl 1():33-44. PubMed ID: 37953111
[TBL] [Abstract][Full Text] [Related]
7. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014).
Kohira N; Hackel MA; Ishioka Y; Kuroiwa M; Sahm DF; Sato T; Maki H; Yamano Y
J Glob Antimicrob Resist; 2020 Sep; 22():738-741. PubMed ID: 32702396
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.
Kayama S; Kawakami S; Kondo K; Kitamura N; Yu L; Hayashi W; Yahara K; Sugawara Y; Sugai M
J Glob Antimicrob Resist; 2024 May; 38():12-20. PubMed ID: 38789082
[TBL] [Abstract][Full Text] [Related]
9.
Abdul-Mutakabbir JC; Nguyen L; Maassen PT; Stamper KC; Kebriaei R; Kaye KS; Castanheira M; Rybak MJ
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0264620. PubMed ID: 34125590
[TBL] [Abstract][Full Text] [Related]
10. Cefiderocol against Multi-Drug and Extensively Drug-Resistant
Zalas-Więcek P; Płachta K; Gospodarek-Komkowska E
Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558842
[TBL] [Abstract][Full Text] [Related]
11. In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium.
Oueslati S; Bogaerts P; Dortet L; Bernabeu S; Ben Lakhal H; Longshaw C; Glupczynski Y; Naas T
Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290010
[TBL] [Abstract][Full Text] [Related]
12. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020.
Kohira N; Hackel MA; Oota M; Takemura M; Hu F; Mizuno H; Sahm DF; Yamano Y
J Glob Antimicrob Resist; 2023 Mar; 32():181-186. PubMed ID: 36513320
[TBL] [Abstract][Full Text] [Related]
13. Analysis of In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli by Broth Microdilution and Disk Diffusion Method: A Single-Center Study in Odisha, India.
Nayak G; Behera B; Mohanty S; Kar P; Jena J
Infect Drug Resist; 2022; 15():5887-5897. PubMed ID: 36237292
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan.
Yamano Y; Ishibashi N; Kuroiwa M; Takemura M; Sheng WH; Hsueh PR
J Glob Antimicrob Resist; 2022 Mar; 28():120-124. PubMed ID: 34958997
[TBL] [Abstract][Full Text] [Related]
15. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
16. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections.
El Ghali A; Kunz Coyne AJ; Lucas K; Tieman M; Xhemali X; Lau S-p; Iturralde G; Purdy A; Holger DJ; Garcia E; Veve MP; Rybak MJ
Microbiol Spectr; 2024 Feb; 12(2):e0310823. PubMed ID: 38206034
[TBL] [Abstract][Full Text] [Related]
17.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
18. Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol.
Daoud L; Al-Marzooq F; Moubareck CA; Ghazawi A; Collyns T
PLoS One; 2022; 17(12):e0277946. PubMed ID: 36580460
[TBL] [Abstract][Full Text] [Related]
19. Activity of Cefiderocol Against
Iregui A; Khan Z; Landman D; Quale J
Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
[TBL] [Abstract][Full Text] [Related]
20. Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32718965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
